Skip to main content
Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

5. References

  1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2024. Available at: http://www.clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed February 20, 2024.
  2. Dabigatran etixilate mesylate capsules (Pradaxa) package insert. Boehringer Ingelheim Pharmaceuticals, Inc., November 2023.
  3. Dabigatran etixilate mesylate pellets (Pradaxa) package insert. Boehringer Ingelheim Pharmaceuticals, Inc., November 2023.
  4. Apixaban tablets (Eliquis) package insert. E.R. Squibb & Sons, L.L.C., April 2021. 
  5. Edoxaban tablets (Savaysa) package insert. Daiichi Sankyo, Inc., October 2023.
  6. Rivaroxaban tablets and granules for suspension (Xarelto) package insert. Janssen Pharmaceuticals, Inc., February 2023.
  7. U.S. Food and Drug Administration. FDA approved first oral blood thinning medication for children. June 2021. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-blood-thinning-medication-children#:~:text=Today%2C%20the%20U.S.%20Food%20and,by%20injection%20for%20at%20least. Accessed March 1, 2022. 
  8. U.S. Food and Drug Administration. FDA approved drug to treat, help prevent types of blood clots in certain pediatric populations. December 2021. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-help-prevent-types-blood-clots-certain-pediatric-populations#:~:text=FDA%20has%20approved%20Xarelto%20(rivaroxaban,days%20of%20injectable%20or%20intravenous. Accessed February 26, 2024.
  9. Stevens SM, Woller SC, Kreuziger LB, et al. Executive summary: antithrombotic therapy for vte disease: second update of the chest guideline and expert panel report. CHEST. 2021;160(6):2247-2259.
  10. Halton J, Brandão LR, Luciani M, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (Diversity): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. The Lancet Haematology. 2021;8(1):e22-e33.
  11. Brandão LR, Albisetti M, Halton J, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020;135(7):491-504.
  12. Bosch A, Albisetti M. Management of venous thromboembolism in children: current recommendations and therapeutic options. Ther Clin Risk Manag. 2020;16:673-679.
  13. Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. The Lancet Haematology. 2020;7(1):e18-e27.
  14. McCrindle BW, Michelson AD, Van Bergen AH, et al. Thromboprophylaxis for children post‐fontan procedure: insights from the universe study. Journal of the American Heart Association. 2021;10(22):e021765.